Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Selling Opioids Is Not A Public Nuisance For Three Reasons, Oklahoma State Appeals Court Rules

Executive Summary

Overturning a $465m verdict against J&J, Oklahoma Supreme Court rejects claim opioid sales violated a public right. It says a manufacturer does not have control of its product once it is sold and cannot be held perpetually liable for its products.

You may also be interested in...



Teva Inks Texas Opioids Settlement And Eyes J&J’s Nationwide ‘Formula’

Teva CEO Kåre Schultz has spoken at great length of the firm’s current standing with opioid-related matters, days after it reached a deal valued at $225m to resolve claims in the state of Texas. A nationwide deal is still top of the Israeli firm’s agenda, with a rough estimate of $3bn-$4bn suggested.

Opioid Jury Verdict May Change Settlement Equation For Sponsors

New York jury finds that Teva and distributor Anda violated state’s public nuisance law in their marketing and distribution of opioids. Such claims had been rejected by two previous courts and the verdict in this case shows the challenges companies face in ongoing litigation.

US FDA Cast As Culpable Player In Opioid Epidemic In Hulu’s Dopesick Series

Show depicts former agency officials approving OxyContin labeling that enabled Purdue to market it as nonaddictive and subsequently refusing pleas to restrict its use.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS145228

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel